PLAT and androgen insensitivity syndrome: Intravenous thrombolysis is the primary approach for the treatment of AIS, and recombinant tissue plasminogen activator (tPA), which is commercially available as alteplase, is currently the only FDA-approved thrombolytic agent (Powers et al, 2019).